BRPI0514236A - compound, use thereof, pharmaceutical composition, and methods for producing 17-desmethylrapamycin or an analogue thereof, to generate a recombinant strain, to prepare a 17-desmethylrapamycin analogue and to generate a 17-desmethylrapamycin analogue - Google Patents

compound, use thereof, pharmaceutical composition, and methods for producing 17-desmethylrapamycin or an analogue thereof, to generate a recombinant strain, to prepare a 17-desmethylrapamycin analogue and to generate a 17-desmethylrapamycin analogue

Info

Publication number
BRPI0514236A
BRPI0514236A BRPI0514236-9A BRPI0514236A BRPI0514236A BR PI0514236 A BRPI0514236 A BR PI0514236A BR PI0514236 A BRPI0514236 A BR PI0514236A BR PI0514236 A BRPI0514236 A BR PI0514236A
Authority
BR
Brazil
Prior art keywords
desmethylrapamycin
analogue
generate
methods
prepare
Prior art date
Application number
BRPI0514236-9A
Other languages
Portuguese (pt)
Inventor
Matthew Alan Gregory
Christine Janet Martin
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of BRPI0514236A publication Critical patent/BRPI0514236A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA PRODUZIR 17-DESMETILRAPAMICINA OU UM ANáLOGO DA MESMA, PARA GERAR UMA CEPA RECOMBINANTE, PARA PREPARAR UM ANáLOGO DE 17-DESMETILRAPAMICINA E PARA GERAR UM ANáLOGO DE 17-DESMETILRAPAMICINA A presente invenção se refere à produção de policetídeos e outros produtos naturais e à biblioteca de compostos e compostos novos individuais. Portanto, em um aspecto, a presente invenção provê 17-desmetilrapamicina e análogos da mesma, métodos para sua produção, incluindo cepas recombinantes, e isolamento e usos dos compostos da invenção. Em um outro aspecto, a presente invenção provê o uso de 17- desmetilrapamicina e análogos da mesma na indução ou manutenção de imunossupressão, na estimulação de regeneração neuronal ou no tratamento de câncer, malignidades de célula B, infecções fúngicas, rejeição ao transplante, doença de enxerto versus hospedeiro, doenças auto-imunes, doenças de inflamação, doença vascular e doenças fibróticas, e na regulação de cura de ferimento.COMPOUND, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND, METHODS FOR PRODUCING 17-DESMETHYRAPAMYCIN OR ANALOG OF THE SAME, TO GENERATE A RECOMBINING CUP, TO PREPARE AN ANALOG OF 17-DEMETHYRAPAMYCIN AND TO GENERATE 17 ANALOGUE refers to the production of polyketides and other natural products and the library of individual compounds and novel compounds. Therefore, in one aspect, the present invention provides 17-demethylrapamycin and analogs thereof, methods for their production, including recombinant strains, and isolation and uses of the compounds of the invention. In another aspect, the present invention provides the use of 17-desmethylrapamycin and analogs thereof in the induction or maintenance of immunosuppression, stimulation of neuronal regeneration or treatment of cancer, B cell malignancies, fungal infections, transplant rejection, disease. graft versus host, autoimmune diseases, inflammation diseases, vascular disease, and fibrotic diseases, and in wound healing regulation.

BRPI0514236-9A 2004-08-11 2005-08-11 compound, use thereof, pharmaceutical composition, and methods for producing 17-desmethylrapamycin or an analogue thereof, to generate a recombinant strain, to prepare a 17-desmethylrapamycin analogue and to generate a 17-desmethylrapamycin analogue BRPI0514236A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417852.1A GB0417852D0 (en) 2004-08-11 2004-08-11 Production of polyketides and other natural products
PCT/GB2005/003158 WO2006016167A2 (en) 2004-08-11 2005-08-11 17-desmethylrapamycin and analogues thereof, methods for their roduction and their use as immunosupressants, anticancer agents, antifungal agents, etc.

Publications (1)

Publication Number Publication Date
BRPI0514236A true BRPI0514236A (en) 2008-06-03

Family

ID=33017292

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514236-9A BRPI0514236A (en) 2004-08-11 2005-08-11 compound, use thereof, pharmaceutical composition, and methods for producing 17-desmethylrapamycin or an analogue thereof, to generate a recombinant strain, to prepare a 17-desmethylrapamycin analogue and to generate a 17-desmethylrapamycin analogue

Country Status (19)

Country Link
US (1) US7803808B2 (en)
EP (2) EP2029611A2 (en)
JP (1) JP2008509895A (en)
KR (1) KR20070052784A (en)
CN (2) CN101056880A (en)
AU (1) AU2005270989B2 (en)
BR (1) BRPI0514236A (en)
CA (1) CA2575582A1 (en)
CR (1) CR8990A (en)
EC (1) ECSP077303A (en)
GB (1) GB0417852D0 (en)
IL (1) IL181171A0 (en)
MX (1) MX2007001809A (en)
NO (1) NO20070686L (en)
NZ (1) NZ553074A (en)
RU (2) RU2430922C2 (en)
UA (1) UA95895C2 (en)
WO (1) WO2006016167A2 (en)
ZA (1) ZA200701622B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896018A2 (en) * 2005-03-11 2008-03-12 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
CN101836980A (en) * 2005-03-11 2010-09-22 比奥蒂卡科技有限公司 Medical use of 39-desmethoxyrapamycin and its analogs
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
DE602007006663D1 (en) 2006-06-12 2010-07-01 Univ Ramot METHOD FOR THE TREATMENT OF CANCER
US8063075B2 (en) 2008-06-10 2011-11-22 Hoffmann-La Roche Inc. Pyrrolidine ether derivatives as NK3 receptor antagonists
EP2646440A4 (en) 2010-11-30 2014-06-18 Univ Johns Hopkins HYBRID CYCLIC LIBRARIES AND SCREENS OF THESE LIBRARIES
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2014100742A2 (en) 2012-12-21 2014-06-26 The Regents Of The University Of California Modulation of expression of acyltransferases to modify hydroxycinnamic acid content
GB201312318D0 (en) 2013-07-09 2013-08-21 Isomerase Therapeutics Ltd Novel methods and compounds
US10774110B2 (en) 2016-02-04 2020-09-15 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
MX2018009405A (en) 2016-02-04 2018-11-09 Univ Johns Hopkins Synthesis and composition of rapafucin libraries.
CA3013783A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Rapaglutins, novel inhibitors of glut and use thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
JP2020507632A (en) * 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. Rapamycin analog
CN108456213B (en) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 Preparation method of 3-fluoro-4-hydroxycyclohexane carboxylate
CN107629994B (en) * 2017-10-25 2021-11-02 中国科学院上海有机化学研究所 A kind of method for constructing FK520 high-yield engineering strain and high-yield strain of Streptomyces hygroscopicus
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
CN109467579B (en) * 2018-11-01 2021-10-15 海南大学 A kind of PKS I type polyketide compound with immunosuppressive activity and preparation method and application thereof
CN110627702B (en) * 2019-10-18 2022-11-15 福建师范大学 Polyketide compound and preparation method and application thereof
EP3854350A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of manufacturing an endoprosthesis
EP3854348A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of attaching a fiber to a surface
EP3854349A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of manufacturing an endoprosthesis
CN115125179B (en) * 2021-03-26 2023-10-27 上海医药工业研究院 Rapamycin-producing genetically engineered bacteria and their applications
US20230104503A1 (en) * 2021-06-25 2023-04-06 The Regents Of The University Of California Small molecule compounds
KR102774027B1 (en) * 2021-12-09 2025-02-27 국립낙동강생물자원관 Micromonospora sp. MS-62 isolated from freshwater sponges having anticancer, anti-algae and anti-inflammation activity and uses thereof
CN118324775B (en) * 2024-03-01 2025-03-21 中山大学附属第五医院 A polyketide compound and its application in preparing medicine for treating pulmonary fibrosis

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993479A (en) 1975-08-04 1976-11-23 Olin Corporation Copper base alloy
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5109112A (en) 1989-01-19 1992-04-28 Merck & Co., Inc. FK-506 cytosolic binding protein
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
WO1992021341A1 (en) 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
US5763590A (en) 1991-10-11 1998-06-09 Vertex Pharmaceuticals, Inc. Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA
US5498597A (en) 1992-01-17 1996-03-12 Dana-Farber Cancer Institute, Inc. FKBP-13, an FK506-binding immunophilin
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5354845A (en) 1993-04-21 1994-10-11 Children's Research Institute FK-506 and rapamycin specific binding immunophilin
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5912253A (en) 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
EP0833828B1 (en) 1995-06-09 2002-11-20 Novartis AG Rapamycin derivatives
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9710962D0 (en) * 1997-05-28 1997-07-23 Univ Cambridge Tech Polyketides and their synthesis
AP1029A (en) 1996-07-05 2001-12-11 Biotica Tech Limited Erythromycins and process for their preparation.
EP1208847B8 (en) 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9814006D0 (en) 1998-06-29 1998-08-26 Biotica Tech Ltd Polyketides and their synthesis
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
AU777997B2 (en) 1999-07-09 2004-11-11 Oregon Health And Science University Compositions and methods for promoting nerve regeneration
AU783158B2 (en) * 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
WO2001034816A1 (en) 1999-10-29 2001-05-17 Kosan Biosciences, Inc. Rapamycin analogs
ATE453719T1 (en) 2000-04-13 2010-01-15 Biotica Tech Ltd GLYCOSYLATED HYBRID COMPOUNDS, THEIR PRODUCTION AND USE
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
GB0019986D0 (en) 2000-08-14 2000-10-04 Biotica Tech Ltd Polyketides and their synthesis
GB0125043D0 (en) 2001-10-17 2001-12-12 Biotica Tech Ltd Production, detection and use of transformant cells
GB0128680D0 (en) 2001-11-29 2002-01-23 Biotica Tech Ltd Hybrid glycosylated products and their production and use
MXPA04008071A (en) 2002-02-19 2004-11-26 Dow Agrosciences Llc Novel spinosyn-producing polyketide synthases.
CA2492153C (en) * 2002-07-16 2012-05-08 Biotica Technology Limited Production of polyketide fkbp-ligand analogues

Also Published As

Publication number Publication date
NO20070686L (en) 2007-04-25
WO2006016167A2 (en) 2006-02-16
EP2471797A2 (en) 2012-07-04
EP2471797A3 (en) 2012-10-17
WO2006016167A3 (en) 2006-04-13
US20090253732A1 (en) 2009-10-08
RU2007108772A (en) 2008-09-20
RU2430922C2 (en) 2011-10-10
AU2005270989A1 (en) 2006-02-16
US7803808B2 (en) 2010-09-28
ECSP077303A (en) 2007-04-26
NZ553074A (en) 2011-01-28
GB0417852D0 (en) 2004-09-15
ZA200701622B (en) 2008-06-25
EP2471797B1 (en) 2016-02-03
JP2008509895A (en) 2008-04-03
RU2009140290A (en) 2011-05-10
IL181171A0 (en) 2007-07-04
CN101056880A (en) 2007-10-17
EP2029611A2 (en) 2009-03-04
CN101805748A (en) 2010-08-18
UA95895C2 (en) 2011-09-26
AU2005270989B2 (en) 2012-04-05
CR8990A (en) 2009-01-14
MX2007001809A (en) 2007-10-08
CA2575582A1 (en) 2006-02-16
KR20070052784A (en) 2007-05-22

Similar Documents

Publication Publication Date Title
BRPI0514236A (en) compound, use thereof, pharmaceutical composition, and methods for producing 17-desmethylrapamycin or an analogue thereof, to generate a recombinant strain, to prepare a 17-desmethylrapamycin analogue and to generate a 17-desmethylrapamycin analogue
Lin et al. Royal jelly-derived proteins enhance proliferation and migration of human epidermal keratinocytes in an in vitro scratch wound model
BR112023018472A2 (en) PSYLOCYBIN COMPOSITIONS, PRODUCTION METHODS AND METHODS OF USE THEREOF
Geller et al. Evaluation of the wound healing properties of Hancornia speciosa leaves
CL2011003346A1 (en) Compounds derived from 2,3-dihydro-5h- [1,3] thiazolo [3,2-a] pyrimidin-5-one, modulators of pi3k; pharmaceutical composition; and use to treat an immune-based disease, cancer, or lung disease in a patient.
BR112014027010A2 (en) use of high dose laquinimod for treatment of multiple sclerosis
Li et al. Quercetin as a promising intervention for rat osteoarthritis by decreasing M1‐polarized macrophages via blocking the TRPV1‐mediated P2X7/NLRP3 signaling pathway
Seo et al. A novel role for earthworm peptide Lumbricusin as a regulator of neuroinflammation
BR112022018645A2 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES, INCLUDING TYPE I AND TYPE II DIABETES MELLITUS AND THYROID DISEASES
MX2023005971A (en) Methods and composition for kras modifications.
Yiemwattana et al. Antibacterial and anti-inflammatory potential of Morus alba stem extract
MD20250033A2 (en) Cannabinoid composition and application thereof in preparation of drug for treating neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease
BR112023022647A2 (en) 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, METHOD OF PREPARATION THEREOF AND MEDICAL USE THEREOF
MX2024014216A (en) Aromatic boron-containing compounds and related insulin analogs
MX2025005597A (en) Novel anti-senescence compounds
Kermani et al. Anti-Leishmania activity of osthole
BRPI0508177A (en) compound, process for the production of compound, pharmaceutical composition, use of compound method for treating a disease and combination product
BRPI0416005A (en) thiazolidinones, in the preparation and use as a medicament
BR112022010498A2 (en) KETOPROFEN COCRYSTAL AND ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME AND THEIR USE
Yoon et al. Skin regeneration effect and chemical composition of essential oil from Artemisia Montana
Bałan et al. Review paper Immunotropic activity of Echinacea. Part I. History and chemical structure
MX2022006052A (en) Caspase 6 inhibitors and uses thereof.
Bian et al. Beneficial effects of extracts from Lucilia sericata maggots on burn wounds in rats
Pattanayak et al. Evaluation of anti-inflammatory activity of Nyctanthes arbortristis leaves
CN107427546A (en) Composition containing Panlong ginseng extract and its pharmaceutical application

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.